Today: 19 May 2026
Browse Category

Biotechnology 28 April 2026 - 18 May 2026

Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

Tonix Pharmaceuticals filed new Phase 1 modeling data showing its experimental Lyme disease antibody, TNX-4800, could maintain serum levels above a proposed protective threshold for six months with a two-dose regimen. Shares rose $1.65 to $15.74 Friday. The company plans a Phase 2 trial in 2027, pending FDA agreement. No Lyme vaccine is currently available in the U.S.
15 May 2026
···
REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO shares fell 37% to $6.31 after its Duchenne muscular dystrophy gene therapy, RGX-202, met the main goal in a late-stage trial. Investors reacted to two serious adverse events and uncertainty over FDA approval. The company reported 93% of patients showed microdystrophin expression at 12 weeks. REGENXBIO said it will seek accelerated approval and targets a 2027 launch.
14 May 2026
····
WORK Medical Technology Group Stock Triples After AI BioToken Deal — What Investors Need to Know

WORK Medical Technology Group Stock Triples After AI BioToken Deal — What Investors Need to Know

WORK Medical Technology Group’s Nasdaq-listed shares surged 206% Monday to $3.92 after announcing an AI partnership with Shanghai Novabioplus Biotechnology. The stock swung between $0.19 and $4.09 before falling 48% in early Tuesday premarket. The companies plan to develop AI-driven models for protein and biological data but disclosed no financial terms or customer details.
12 May 2026
···
Moderna Stock Gets Fresh Hantavirus Jolt As Cruise-Ship Outbreak Widens

Moderna Stock Gets Fresh Hantavirus Jolt As Cruise-Ship Outbreak Widens

Moderna’s early-stage hantavirus vaccine research drew renewed attention after a deadly Andes virus outbreak on the MV Hondius cruise ship, with six confirmed cases and three deaths reported. Moderna shares closed up nearly 12% Friday. WHO and ECDC rated the broader public risk as low, but recommended a 42-day quarantine for passengers. No approved vaccine or treatment for Andes virus exists, according to the CDC.
11 May 2026
··
Moderna Stock Surges on Hantavirus Vaccine Research as MRNA Investors Eye Flu and Cancer Pipeline

Moderna Stock Surges on Hantavirus Vaccine Research as MRNA Investors Eye Flu and Cancer Pipeline

Moderna confirmed early-stage research on hantavirus vaccines with U.S. Army and Korea University partners, following a deadly outbreak on the MV Hondius cruise ship. Eight cases, including three deaths, have been reported; six cases are confirmed. Moderna shares rose 11.9% to $54.35. Spain and several EU countries are preparing evacuations as the ship nears Tenerife.
9 May 2026
··
Moderna Stock Surges on Hantavirus Vaccine News as Cruise Outbreak Puts mRNA Pipeline Back in Focus

Moderna Stock Surges on Hantavirus Vaccine News as Cruise Outbreak Puts mRNA Pipeline Back in Focus

Moderna shares rose about 10% Friday after the company announced research into vaccines for hantaviruses amid a deadly Andes virus outbreak linked to the MV Hondius cruise ship. WHO reported eight cases and three deaths, with five confirmed as hantavirus. Moderna’s vaccine program is in early stages, with commercial availability still years away. The U.S. is arranging a repatriation flight for 17 Americans from the ship.
8 May 2026
·
Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeline Back in Focus

Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeline Back in Focus

Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, including $300 million upfront, to gain access to a mid-stage eye-disease drug, PER-001. Eylea, Bayer’s top-selling eye drug, saw 2025 sales fall 5.9% to €3.11 billion amid generic competition. The deal awaits antitrust and shareholder approval. PER-001 is in Phase II trials for glaucoma and diabetic retinopathy.
6 May 2026
··
Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Ernexa Therapeutics said its ERNA-101 cell therapy plus PD-1 blockade cleared tumors and achieved 100% long-term survival in preclinical ovarian cancer models. Shares jumped about 60% after the announcement, trading between $3.70 and $7.66. The company remains preclinical and recently completed a 1-for-25 reverse stock split to maintain its Nasdaq listing.
6 May 2026
···
Avalo Therapeutics Stock Jumps As $375 Million Raise Follows Phase 2 HS Trial Win

Avalo Therapeutics Stock Jumps As $375 Million Raise Follows Phase 2 HS Trial Win

Avalo Therapeutics priced a $375 million public offering after reporting positive Phase 2 results for abdakibart in hidradenitis suppurativa. The company will sell 19.73 million shares at $17.75 each and pre-funded warrants for 1.4 million shares. Shares rose 34% to $21.73 by midday. The Phase 2 trial showed HiSCR75 response rates of over 42% for both dosing regimens versus 25.6% for placebo.
6 May 2026
··
GeneDx Stock Crash: WGS Plunges After Guidance Cut Raises Reimbursement Fears

GeneDx Stock Crash: WGS Plunges After Guidance Cut Raises Reimbursement Fears

GeneDx shares dropped 51% to $33.12 after the company cut its 2026 revenue forecast and lowered full-year guidance to $475–$490 million. First-quarter revenue rose 17% to $102.3 million, but missed expectations as reimbursement rates and product mix hurt sales. The company posted an adjusted net loss of $8.2 million. Management maintained its target for positive adjusted net income this year.
5 May 2026
····
Lunai Bioworks Stock: $20 Million Patent Deal Puts Nasdaq Fight in Focus

Lunai Bioworks Stock: $20 Million Patent Deal Puts Nasdaq Fight in Focus

Lunai Bioworks issued $20 million in Series B preferred stock to acquire Neurobridge IP Holdings’ CNS drug-delivery and neurotherapeutic patents, closing the deal May 1. The company said the transaction lifts its stockholders’ equity above Nasdaq’s $2.5 million listing minimum. Lunai shares traded at $0.3246 Monday, leaving its market value at $7.6 million. The acquired assets consist solely of patents, with no cash paid.
4 May 2026
···
Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Cabaletta Bio shares surged 32% after the company reported early results from its cell-therapy trial and priced a $150 million stock offering with participation from Eli Lilly and others. Two of four pemphigus vulgaris patients showed clinical activity with rese-cel, its experimental CAR-T therapy. The company expects to fund operations into mid-2027. New data will be presented at the ASGCT meeting on May 14.
4 May 2026
····
Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Mirum Pharmaceuticals said its drug volixibat met the main goal in a 158-patient Phase 2b trial for primary sclerosing cholangitis, reducing itch scores more than placebo. Shares rose about 9% after the announcement. The company plans a pre-NDA meeting with the FDA this summer and aims to file for U.S. approval in the second half of 2026. No FDA-approved therapies currently exist for this rare liver disease.
4 May 2026
··
Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes

Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes

Celcuity Inc. shares rose nearly 16% Monday after reporting its breast cancer drug gedatolisib met the main goal in a late-stage trial for patients with PIK3CA-mutant tumors. The company plans to submit the new data to the FDA as a supplemental application. Celcuity traded at $145.54, up $19.89, with a market value near $6.9 billion. A July 17 FDA decision on gedatolisib for a related use remains pending.
4 May 2026
···
Why iSpecimen Stock Whipsawed After Its 1-for-40 Reverse Split

Why iSpecimen Stock Whipsawed After Its 1-for-40 Reverse Split

iSpecimen Inc. shares fell 8.2% to $4.80 Friday after volatile trading, following a 1-for-40 reverse stock split aimed at meeting Nasdaq’s minimum bid price. The split reduced outstanding shares from 52.6 million to about 1.3 million. Nasdaq has given the company until May 18 to regain compliance. The annual meeting is set for May 8 after previous adjournments due to lack of quorum.
1 May 2026
··
Alexandria Real Estate Stock Slides as Lab-Leasing Weakness Overshadows Q1 Profit Jump

Alexandria Real Estate Stock Slides as Lab-Leasing Weakness Overshadows Q1 Profit Jump

Alexandria Real Estate Equities shares fell 9% Tuesday after first-quarter adjusted FFO dropped to $1.73 a share from $2.30 a year earlier and revenue declined to $671 million. The company lowered its 2026 occupancy and rental-rate assumptions but kept its adjusted FFO midpoint at $6.40. Net income rose to $358.9 million on a debt-repurchase gain. BNP Paribas Exane cut its price target to $44.
28 April 2026
····
Baiya International’s $1 Million BNB Bet Sends BIYA Stock Sharply Higher

Baiya International’s $1 Million BNB Bet Sends BIYA Stock Sharply Higher

Baiya International Group said Binance Coin (BNB) won 89.2% of a public vote and will be the first core digital asset in its new “Cryptocurrency Ark Plan.” BIYA shares surged 82% to $1.42 on Nasdaq, with trading volume near 184 million. The company plans an initial $1 million BNB purchase and will use trading gains for share buybacks. Recent filings indicate possible equity dilution as Baiya moves into crypto trading.
28 April 2026
··
1 2 3 … 17

Stock Market Today

  • Tempus AI (TEM) Shares Decline Amid Valuation Debate
    May 18, 2026, 9:20 PM EDT. Tempus AI (TEM) shares have dropped 22% over the past month and are down 30% year to date, reflecting investor concerns about growth and risk in its healthcare AI business. At $43.62 per share, TEM trades below the consensus analyst target price of $67.20, suggesting a potential 35% undervaluation based on expectations of revenue growth, improved profit margins, and a higher earnings multiple. However, analysts' price targets vary widely, ranging from $35 to $100, highlighting differing views on the company's future. Key risks include competition, reimbursement delays, and slower revenue from AI and data services. Investors are advised to weigh these factors carefully amid mixed market sentiment.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

AMC Jumps But Caution Lingers for Traders

AMC Jumps But Caution Lingers for Traders

18 May 2026
AMC Entertainment shares rose 6.25% to $1.36 on Monday, outpacing broader markets as trading volume stayed below average. The company reported first-quarter food-and-beverage revenue of $347.3 million, up from $283.4 million a year ago. AMC expanded its Feature Fare menu at over 400 U.S. theaters. A recent filing showed AMC issued 12.4 million shares to cancel $13.6 million in exchangeable notes.
Go toTop